BCL2 and lung cancer: In this study, treatment with the GAN/MTX combination downregulated the mRNA expression of survivin and Bcl-2 to 0.55 and 0.43 folds, respectively, as compared to their individual treatment in lung cancer cells (Figure 5D,E).